Cellebrite DI Ltd. (CLBT) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2025
Loading P/E history...
CLBT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Cellebrite DI Ltd. (CLBT) trades at a price-to-earnings ratio of 44.5x, with a stock price of $13.81 and trailing twelve-month earnings per share of $0.31.
The current P/E is 36% above its 5-year average of 32.8x. Over the past five years, CLBT's P/E has ranged from a low of 4.7x to a high of 73.0x, placing the current valuation at the 56th percentile of its historical range.
Compared to the Technology sector median P/E of 27.7x, CLBT trades at a 61% premium to its sector peers. The sector includes 359 companies with P/E ratios ranging from 0.0x to 184.2x.
The PEG ratio of 0.76 (P/E divided by 123% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, CLBT commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CLBT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CLBT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $34B | 282.7 | - | -69% | |
| $455M | 6.4Lowest | - | +30% | |
| $506M | 40.9 | - | -88% | |
| $2B | 23.2 | 1.62 | +21% | |
| $11B | 22.0 | 1.81 | +20% | |
| $4B | 12.2 | 0.73 | +7% | |
| $17B | 11.8 | 0.57Best | +21% | |
| $13B | 10.6 | 0.65 | +58%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CLBT Historical P/E Data (2021–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $18.03 | $0.31 | 58.3x | +78% |
| FY2025 Q3 | $18.53 | $0.31 | 60.4x | +84% | |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $6.09 | $0.12 | 52.2x | +59% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $4.36 | $0.62 | 7.1x | -78% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $3.92 | $0.83 | 4.7x | -86% |
| FY2022 Q2 | $5.10 | $0.75 | 6.8x | -79% | |
| FY2022 Q1 | $6.40 | $0.62 | 10.3x | -69% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $8.02 | $0.36 | 22.2x | -32% |
| FY2021 Q3 | $9.26 | $0.13 | 73.0x | +123% |
Average P/E for displayed period: 32.8x
See CLBT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLBT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLBT vs NVDA
Side-by-side business, growth, and profitability comparison vs NVIDIA Corporation.
Start ComparisonCLBT — Frequently Asked Questions
Quick answers to the most common questions about buying CLBT stock.
Is CLBT stock overvalued or undervalued?
CLBT trades at 44.5x P/E, above its 5-year average of 32.8x. The 56th percentile ranking indicates a premium to historical valuation.
How does CLBT's valuation compare to peers?
Cellebrite DI Ltd. P/E of 44.5x compares to sector median of 27.7x. The premium reflects expected growth above peers.
What is CLBT's PEG ratio?
CLBT PEG ratio is 0.76. Below 1.0 indicates valuation is supported by earnings growth rate. Historical P/E data spans 2021-2025.